



**Contact:** Jane Homan  
**Location:** Madison, WI  
**Email:** jane\_homan@iogenerics.com  
**Tel:** 608 310 9540  
**Website:** www.ioenerics.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
 National Institutes of Health



National Institutes of Health Commercialization Assistance Program  
 (NIH-CAP)

## Company Overview

**Industry Sector:** Drug Discovery, Infectious Disease Therapeutics

**Company Overview:** ioGenetics is an early stage company which was created by spin-off from another Founders' company. It has achieved considerable progress in biotherapeutic technology development and has pioneered a novel antimicrobial platform called Directed Biocides™, distinct in structure and function from current antibiotics and anti-parasitic drugs. Directed Biocides™ are fusion protein molecules which employ a targeting component to direct an antimicrobial peptide or lytic enzyme to a specific pathogen, destroying the microbe and recruiting the host response.

**Target Market(s):** Anti-infectives/ antimicrobials for human and veterinary markets

## Key Value Drivers

**Technology\*:** ioGenetics' lead therapeutic is an oral Directed Biocide™ for treating cryptosporidiosis, which affects both humans and animals.

**Competitive Advantage:** ioGenetics uses a "rational design" process to design and construct fusion proteins targeting a broad range of microorganisms. The time required from design to testing is short, and we can rapidly scale up production. Directed Biocides™ offer an alternative to traditional antibiotics and anti-parasitic drugs that have long discovery and development times.

**Plan & Strategy:** ioGenetics will design and develop antimicrobial fusion proteins, either directly with collaboration partners or with the goal of future out-licensing. ioGenetics is also developing therapeutics for neglected tropical diseases through federal grant and non-profit funding. Our anti-cryptosporidial therapeutic is in animal trials and will be commercialized first as an animal health product.

\*Technology funded by the NIAID and being commercialized under the NIH-CAP

## Management

### Leadership:

Jane Homan, Ph.D., MRCVS, Chief Executive Officer  
 Robert Bremel, Ph.D., Chief Scientific Officer  
 Michael Imboden, Ph.D., Director of R&D

### Advisors:

Herman Van Cauteren, DVM, Pharmaparacelsus BVBA  
 Robert Woestenborghs, MSC, Pharmaparacelsus BVBA  
 Pierre Veys, DVM, Pharmaparacelsus BVBA  
 Michael Riggs, DVM, PhD, University of Arizona  
 Jorge Osorio, DVM, PhD, University of Wisconsin

## Antimicrobials in ioGenetics' pipeline

